Beneath today's data, two currents are pulling in opposite directions, and the fork between them is becoming structural. The ibogaine literature is not merely accumulating risk signals — it is actively sorting the field. What is forming is a formalized bifurcation between natural ibogaine, which will increasingly require mandatory cardiac monitoring protocols under forthcoming FDA guidance, and synthetic analogs engineered to preserve the anti-addiction mechanism while eliminating the QT liability. This is not a setback dressed as progress — it is the ecosystem self-correcting toward a more durable architecture. The analog pathway, combined with veteran-specific compassionate use carve-outs, represents the highest trajectory genuinely available from here: slower than advocates want, safer than the current gray zone permits. Meanwhile, the psilocybin-cocaine finding opens a second fork — away from the depression-centric commercialization narrative that has dominated since 2020, toward a broader pharmacological mandate. If Phase 3 trials follow in 2027, as the swarm projects with 74% confidence, the regulatory and investment thesis for psilocybin expands significantly, and COMPASS, carrying the deepest Phase 3 infrastructure, becomes structurally positioned even as near-term equity pressure persists.
There are veterans tonight who cannot wait for 2028. There are families for whom the current opioid treatment ceiling — methadone, buprenorphine, and relapse — is not a policy abstraction but a weekly lived reality. The ibogaine cardiac debate can feel, from inside a VA waiting room or a recovery house, like scientists arguing about the color of a door that has not yet been opened. What the bifurcation actually offers those people — if it proceeds along its highest trajectory — is something more durable than rushed access: a version of ibogaine medicine that their cardiologists can work alongside, that their surgeons will not refuse, that the VA system can eventually absorb. That is worth naming clearly, even as the timeline asks more patience of the people who have already given the most.
The science is catching up to what the plants have always known. OOTW exists at that exact moment of convergence — the data and the mystery meeting each other.
The future does not wait for permission — it arrives through those who are ready.
80%
No classical psychedelic will be rescheduled federally before 2028
Classical psychedelics like psilocybin, LSD, and mescaline are illegal Schedule I drugs (meaning the DEA says they have no medical use). Rescheduling means moving them to a lower schedule so doctors can prescribe them. The FDA and DEA both have to approve this, and the whole process—from an FDA recommendation to final DEA approval—takes 18–24 months. No psychedelic company has filed the paperwork for FDA approval yet, so the earliest an FDA recommendation could come is 2026–2027, making 2028 the earliest possible rescheduling date.
→ Federal legalization of psychedelics won't happen before 2028 because the approval process takes 3+ years minimum.
Resolves: 2028-01-01 · USA
REGULATION
the precise call ▾
Federal rescheduling of any classical psychedelic will not occur before 2028, due to DEA independent scheduling process adding 18-24 months beyond any FDA action. No FDA approval recommendation for any classical psychedelic (psilocybin, LMA, mescaline) is currently on a timeline that would allow DEA scheduling completion before 2028. MDMA-assisted therapy was rejected in 2024; psilocybin NDA submissions are not yet filed. DEA scheduling reviews historically t
78%
DEA delays psilocybin access by 18+ months after any FDA approval
The DEA (Drug Enforcement Administration—the federal agency that classifies illegal drugs) has its own separate legal power to review and approve drugs, independent of the FDA (the US drug regulator). If the FDA approves psilocybin for medical use, the DEA will launch its own formal review that typically takes 18+ months to complete. This matters because patients and researchers have to wait even after the FDA says yes.
→ The DEA's separate legal power means two government reviews instead of one, and the second one is slow.
Resolves: 2028-06-01 · USA
REGULATION
the precise call ▾
DEA will initiate formal scheduling review proceedings for psilocybin within 6 months of any FDA approval recommendation, extending access timelines by minimum 18 months. DEA's independent scheduling authority under the CSA is statutory and not overridden by congressional pressure. Historical precedent (e.g., MDMA scheduling delays) supports DEA exercising independent review. The 18-month minimum extension is grounded in typical DEA scheduling timelines. Confidence s
75%
FDA mandates heart monitoring for ibogaine, delaying veteran therapy access
Ibogaine (a plant-derived compound) causes a known heart rhythm problem called QT prolongation—the time it takes your heart's electrical system to reset after each beat. The FDA has documented adverse events and will require mandatory EKG (heart monitoring) before patients can receive ibogaine in clinical trials. This adds 12–18 months to the timeline because the FDA has to write new safety rules, and study teams have to redesign their protocols to include the monitoring.
→ The FDA will require heart monitoring for ibogaine, which slows down getting it to patients by over a year.
Resolves: 2027-03-01 · USA
REGULATION
the precise call ▾
FDA will issue a formal ibogaine cardiac safety guidance document requiring mandatory QT monitoring protocols before any IND expansion, slowing veteran access trials by 12-18 months. Documented QT prolongation adverse events in ibogaine literature and FDA's own adverse event surveillance create regulatory obligation to issue formal guidance. Multiple cardiac safety papers published in close succession signal a literature inflection point that FDA reviewers cannot ignore. Mandato
62%
A serious retreat injury will trigger state-level safety crackdowns by 2026
Oregon and Colorado now allow licensed psychedelic retreat centers to operate legally. These programs are expanding fast, but safety standards vary widely between operators. A documented serious injury or death at one of these commercial retreats is likely to get major newspaper and TV coverage. When that happens, state regulators will launch emergency reviews and probably create stricter safety rules. This matters because it could slow down the entire industry's growth and change how these businesses operate.
→ A serious incident at a commercial psychedelic retreat will probably get national news coverage and trigger state safety crackdowns.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
A documented serious adverse event at a commercial psychedelic retreat will receive major national media coverage before end of 2026, triggering emergency state-level regulatory review in Oregon or Colorado. Oregon's licensed psilocybin service center program launched in 2023 and is scaling; Colorado's program is in early rollout. Rapid commercial expansion with heterogeneous operator safety standards increases adverse event probability. National media has demonstrated appetite for psychedelic coverage.
55%
Ibogaine splits into two paths: natural (restricted) and synthetic (faster approval)
Ibogaine causes heart rhythm problems that synthetic versions of the same molecule (or chemically similar compounds) may not cause. The FDA and investment companies are noticing this and moving toward a two-track approach: natural ibogaine gets heavy restrictions and mandatory heart monitoring, while new synthetic versions developed in labs get faster approval because they don't carry the same cardiac risk. By 2027, this split will probably be formalized in FDA guidance or new laws. This matters because it means natural ibogaine stays harder to access, while synthetic alternatives move faster toward patients.
→ The FDA will treat natural ibogaine and synthetic alternatives as separate drugs with different safety rules and timelines by 2027.
Resolves: 2027-12-31 · USA
REGULATION
the precise call ▾
Ibogaine cardiac safety documentation will drive regulatory and investment bifurcation between natural ibogaine (restricted, mandatory monitoring) and synthetic analogs (accelerated development), with distinct treatment pathways formalized in FDA guidance or legislation by end of 2027. The scientific and regulatory logic for bifurcation is sound: natural ibogaine's cardiac risk profile (QT prolongation, documented fatalities) creates a distinct regulatory burden that synthetic analogs without ibogaine's cardiac mechanism can avoid. Investor capital is already moving toward analog